Hydrochloric Acid

Hydrochloric Acid

SCHEMBL143943

Cl.Oc1ccc(CCl)c2cccnc12

nearest known ligand 0.72

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA known ✓ P10253 2/20 0.72
HSP90AA1 known ✓ P07900 1/20 0.59
KDM4E B2RXH2 11/20 0.72
LMNA P02545 5/20 0.72
L3MBTL1 Q9Y468 5/20 0.72
HTT P42858 4/20 0.72
NPC1 O15118 3/20 0.72
RAB9A P51151 3/20 0.72
SMN1; SMN2 Q16637 2/20 0.72
ALOX12 P18054 3/20 0.62
PAX8 Q06710 1/20 0.62
NPSR1 Q6W5P4 1/20 0.62
MAPT P10636 4/20 0.59
BRD4 O60885 4/20 0.59
METAP2 P50579 1/20 0.59
METAP1 P53582 1/20 0.59
TP53 P04637 4/20 0.58
ALDH1A1 P00352 3/20 0.58
TDP1 Q9NUW8 2/20 0.58
POLB P06746 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL2525083 1.00 KDM4E (0.72) KDM4ELMNAL3MBTL1HTTNPC1
Hydrochloric Acid SCHEMBL31286548 1.00 KDM4E (0.72) KDM4ELMNAL3MBTL1HTTNPC1
SCHEMBL112193 0.98 KDM4E (0.74) KDM4ELMNAL3MBTL1HTTNPC1
SCHEMBL10156363 0.85 KDM4E (0.70) KDM4ELMNAL3MBTL1HTTNPC1
SCHEMBL29203716 0.84 KDM4E (0.74) KDM4ELMNAL3MBTL1HTTNPC1
SCHEMBL9177673 0.84 KDM4E (0.79) KDM4ELMNAL3MBTL1HTTNPC1
SCHEMBL31237495 0.84 KDM4E (0.79) KDM4ELMNAL3MBTL1HTTNPC1
SCHEMBL30159468 0.84 KDM4E (1.00) KDM4ELMNAL3MBTL1HTTNPC1
SCHEMBL1782934 0.84 KDM4E (1.00) KDM4ELMNAL3MBTL1HTTNPC1
SCHEMBL15155384 0.83 KDM4E (0.68) KDM4ELMNAL3MBTL1HTTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120113681-A Composite disinfectant containing chlorine dioxide and preparation process thereof 山东兆冠药业有限公司 2025-06-10 CN claimed
CN-119605800-A Oilfield water injection bactericide containing plant sterilization component and preparation method thereof 郑州德融科技有限公司 2025-03-14 CN claimed
CN-118389912-B Rare earth modified aluminum alloy and preparation method thereof 北京钜嘉机械有限公司 2024-11-12 CN claimed
CN-118389912-A Rare earth modified aluminum alloy and preparation method thereof 北京钜嘉机械有限公司 2024-07-26 CN claimed
CN-116461169-B Efficient heat-dissipating plate for automobile control room equipment cabinet and preparation method thereof 江阴百士特控制显示设备有限公司 2024-04-26 CN claimed
CN-116461169-A Efficient heat-dissipating plate for automobile control room equipment cabinet and preparation method thereof 江阴百士特控制显示设备有限公司 2023-07-21 CN claimed
CN-113072687-B Carbazole porous polymer containing 8-hydroxyquinoline group, and preparation method and application thereof 东南大学 2022-12-13 CN claimed
CN-113072687-A Carbazole porous polymer containing 8-hydroxyquinoline group, and preparation method and application thereof 东南大学 2021-07-06 CN claimed
EP-3137079-A1 INHIBITORS OF JMJD2C AS ANTICANCER AGENTS The J. David Gladstone Institutes (US) 2017-03-08 EP claimed
US-20170044107-A1 Inhibitors of JMJD2C as Anticancer Agents THE J. DAVID GLADSTONE INSTITUTES 2017-02-16 US claimed
WO-2015167874-A1 INHIBITORS OF JMJD2C AS ANTICANCER AGENTS THE J. DAVID GLADSTONE INSTITUTES (US) 2015-11-05 WO claimed
CN-104415765-A Preparation method of Ru-Ni bimetallic based ordered mesoporous carbon catalyst SUZHOU OST ADVANCED MATERIALS CO LTD 2015-03-18 CN claimed
CN-101597315-B Organic metal coordination compound gelator and luminous gel composed of same UNIV BEIJING 2011-05-11 CN claimed
CN-101597315-A A kind of organometallic complex gel factor reaches by its luminous gel that constitutes UNIV BEIJING (CN) 2009-12-09 CN claimed
CN-1288151-C Metal complex type luminous material containing electron injection group and its preparation method UNIV SHANXI (CN) 2006-12-06 CN claimed
CN-1263822-C Luminous material of metal complex type containing hole transmission group and preparation process thereof UNIV SHANXI (CN) 2006-07-12 CN claimed
CN-1597682-A Metal complex type luminous material containing electron injection group and its preparation method UNIV SHANXI (CN) 2005-03-23 CN claimed
CN-1597838-A Luminous material of metal complex type containing hole transmission group and preparation process thereof UNIV SHANXI (CN) 2005-03-23 CN claimed
EP-4622962-A1 SMALL MOLECULAR WEIGHT CHEMICAL COMPOUND TO ANTAGONIZE EPH-EPHRIN TETRAMERIZATION AND INHIBIT BIDIRECTIONAL SIGNALING The Board of Regents of the University of Texas System (US) 2025-10-01 EP disclosed
US-4317887-A NUCLEOPHILIC-MODIFIED POLYACRYLAMIDE, POLYSTYRENE, AND DIVINYLBENZENE-STYRENE COPOLYMER; ION EXCHANGE RESINS; FIREPROOFING YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) 1982-03-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170044107-A1 Inhibitors of JMJD2C as Anticancer Agents KDM2A, KDM1B, KDM5C GAA 4162/4885HSP90AA1 1397/4885KDM4E 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.